'Lumpy' Provenge sales and uncertain 2012 guidance pull spiky Dendreon down
This article was originally published in Scrip
Executive Summary
Observers and analysts have still yet to see a convincing upward trend in Dendreon's sales of its only approved product, the prostate cancer immunotherapy Provenge (sipuleucel-T). But they are reassured by the practical and intensive remediative measures being enacted by the company in 2012.